Filtered By:
Specialty: Drugs & Pharmacology
Condition: Heart Failure
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 434 results found since Jan 2013.
Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials
ConclusionsThere were no demonstrable treatment differences across SGLT2 inhibitors across cardiovascular, renal, and metabolic outcomes, although this needs to be interpreted considering the wide confidence intervals, limited number of included studies, and heterogeneity present. Future research of different SGLT2 inhibitors in head-to-head studies is warranted to determine if there is a drug class effect.
Source: European Journal of Clinical Pharmacology - May 3, 2021 Category: Drugs & Pharmacology Source Type: research
Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Hepatitis C virus (HCV) infection is a systemic disease associated with multiple significant extrahepatic manifestations. Emerging studies indicate association between the HCV infection and a higher incidence of major adverse cardiovascular events such as: coronary artery disease, heart failure, stroke and peripheral artery disease, when compared to general population. Atherosclerosis is a common pathophysiologic mechanism of cardiovascular disease (CVD) development which is the leading cause of mortality in the Western world. Proposed mechanisms of HCV-induced atherosclerosis includes systemic inflammation due to the chro...
Source: Frontiers in Pharmacology - May 11, 2021 Category: Drugs & Pharmacology Source Type: research
Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950
Pharmacol Rev. 2021 Jul;73(3):968-1000. doi: 10.1124/pharmrev.120.000171.ABSTRACTActivation of the Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome drives release of the proinflammatory cytokines interleukin (IL)-1β and IL-18 and induces pyroptosis (lytic cell death). These events drive chronic inflammation, and as such, NLRP3 has been implicated in a large number of human diseases. These range from autoimmune conditions, the simplest of which is NLRP3 gain-of-function mutations leading to an orphan disease, cryopyrin-associated period syndrome, to large disease burden indications, such as atheroscl...
Source: Pharmacological Reviews - June 12, 2021 Category: Drugs & Pharmacology Authors: Sarah E Corcoran Reena Halai Matthew A Cooper Source Type: research
Mildly Increased Renin Expression in the Absence of Kidney Injury in the Murine Transverse Aortic Constriction Model
Cardiorenal syndrome type 2 is characterized by kidney failure as a consequence of heart failure that affects >50% of heart failure patients. Murine transverse aortic constriction (TAC) is a heart failure model, where pressure overload is induced on the heart without any systemic hypertension or its consequences. Whether renal function is altered in this model is debated, and if so, at which time post-TAC renal dysfunction starts to contribute to worsening of cardiac function. We therefore studied the effects of progressive heart failure development on kidney function in the absence of chronically elevated systemic bloo...
Source: Frontiers in Pharmacology - June 15, 2021 Category: Drugs & Pharmacology Source Type: research
Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases
Cardio-Cerebrovascular Disease is a collective term for cardiovascular disease and cerebrovascular disease, being a serious threat to human health. A growing number of studies have proved that the content of inflammatory factors or mediators determines the stability of vascular plaque and the incidence of cardio-cerebrovascular event, and involves in the process of Cardio-Cerebrovascular Diseases. Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, my...
Source: Frontiers in Pharmacology - August 24, 2021 Category: Drugs & Pharmacology Source Type: research
Adverse Cardiovascular Effects of Anti-COVID-19 Drugs
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 infection is the cause of the ongoing global pandemic. Mortality from COVID-19 infection is particularly high in patients with cardiovascular diseases. In addition, COVID-19 patients with preexisting cardiovascular comorbidities have a higher risk of death. Main cardiovascular complications of COVID-19 are myocardial infarction, myocarditis, acute myocardial injury, arrhythmias, heart failure, stroke, and venous thromboembolism. Therapeutic interventions in terms of drugs for COVID-19 have many cardiac adverse effects. Here, we review the relative the...
Source: Frontiers in Pharmacology - August 25, 2021 Category: Drugs & Pharmacology Source Type: research
Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Curr Pharm Des. 2021 Sep 2. doi: 10.2174/1381612827666210902152539. Online ahead of print.ABSTRACTVenous thromboembolism clinically presents as deep venous thrombosis or acute pulmonary embolism and is globally recognized as the third most frequent acute cardiovascular syndrome after myocardial infarction and stroke. Although pulmonary embolism does not typically cause severe pulmonary hypertension in the acute setting, thrombus organization and fibrosis can lead to stenosis or obliteration of pulmonary arteries in a minority of patients, which in turn result in severe pulmonary hypertension and right heart failure. This d...
Source: Current Pharmaceutical Design - September 3, 2021 Category: Drugs & Pharmacology Authors: Nikolaos Papakonstantinou Polydoros Kampaktsis Filippos-Paschalis Rorris Ilias Doulamis Aspasia Tzani Sotirios Katsaridis Dimitrios Avgerinos Source Type: research
A mini-review on the impact of COVID 19 on vital organs
Biomed Pharmacother. 2021 Sep 4;143:112158. doi: 10.1016/j.biopha.2021.112158. Online ahead of print.ABSTRACTCOVID-19 (Corona Virus Disease-2019) is an infectious disease caused by a novel coronavirus, known as the acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This is a highly contagious disease that has already affected more than 220 countries globally, infecting more than 212 million people and resulting in the death of over 4.4 million people. This review aims to highlight the pertinent documentary evidence upon the adverse effects of the SARS-CoV-2 infection on several vital human organs. SARS-CoV-2 primarily ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 10, 2021 Category: Drugs & Pharmacology Authors: Muhammad Dawood Shah Aini Simon Sumeh Muhammad Sheraz Muthu Subash Kavitha Balu Alagar Venmathi Maran Kenneth Francis Rodrigues Source Type: research
Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
ConclusionRoxadustat improved hemoglobin similarly to ESA while demonstrating comparable cardiovascular and overall safety profiles in a wide spectrum of dialysis-dependent patients with anemia of CKD. Roxadustat represents an oral alternative to ESAs for achieving a target hemoglobin for anemia of CKD in dialysis-dependent patients.
Source: Advances in Therapy - September 14, 2021 Category: Drugs & Pharmacology Source Type: research
Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials
ConclusionsThere were no demonstrable treatment differences across SGLT2 inhibitors across cardiovascular, renal, and metabolic outcomes, although this needs to be interpreted considering the wide confidence intervals, limited number of included studies, and heterogeneity present. Future research of different SGLT2 inhibitors in head-to-head studies is warranted to determine if there is a drug class effect.
Source: European Journal of Clinical Pharmacology - September 21, 2021 Category: Drugs & Pharmacology Source Type: research
The Impact of Urate-Lowering Therapy in Post-Myocardial Infarction Patients: Insights from a Population-Based, Propensity Score-Matched Analysis
Clin Pharmacol Ther. 2021 Oct 31. doi: 10.1002/cpt.2473. Online ahead of print.ABSTRACTThe role of urate-lowering therapy (ULT) for the primary prevention of cardiovascular events has been widely discussed, but its evidence for the secondary prevention of myocardial infarction (MI) is limited. Therefore, we conduct a population-based, propensity score-matched cohort study to investigate the cardiovascular outcomes among post-MI patients with and without ULT. A total of 19,042 newly diagnosed in-hospital MI patients were selected using the Taiwan National Health Insurance Database between 1 January 2005 and 31 December 2016...
Source: Clinical Pharmacology and Therapeutics - October 31, 2021 Category: Drugs & Pharmacology Authors: Chi-Jung Tai Chin-Chung Wu Kun-Tai Lee Tzyy-Guey Tseng Hui-Chun Wang Fang-Rong Chang Yi-Hsin Yang Source Type: research
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that improve glycemic control by limiting urinary glucose reuptake in the proximal tubule. SGLT2-is might suppress atherosclerotic processes and ameliorate the prognosis of patients with diabetes mellitus diagnosed with or at high risk of atherosclerotic cardiovascular disease (ASCVD). In this mini review, we examine the role of SGLT2-is in the development and progression of atherosclerosis throughout its spectrum, from subclinical atherosclerosis to ASCVD.Data Sources—PubMed and Google Scholar were searched for publications related to...
Source: Frontiers in Pharmacology - November 5, 2021 Category: Drugs & Pharmacology Source Type: research
